{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:04:06Z","timestamp":1782306246980,"version":"3.54.5"},"reference-count":41,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T00:00:00Z","timestamp":1668643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012665","name":"Institute for Clinical Evaluative Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Life\u2010prolonging therapies (LPTs) are rapidly evolving for the treatment of advanced prostate cancer, although factors associated with real\u2010world uptake are not well characterized.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this cohort of prostate\u2010cancer decedents, we analyzed factors associated with LPT access. Population\u2010level databases from Ontario, Canada identified patients 65\u2009years or older with prostate cancer receiving androgen deprivation therapy and who died of prostate cancer between 2013 and 2017. Univariate and multivariable analyses assessed the association between baseline characteristics and receipt of LPT in the 2\u2009years prior to death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 3575 patients who died of prostate cancer, 40.4% (<jats:italic>n<\/jats:italic>\u00a0=\u00a01443) received LPT, which comprised abiraterone (66.3%), docetaxel (50.3%), enzalutamide (17.2%), radium\u2010223 (10.0%), and\/or cabazitaxel (3.5%). Use of LPT increased by year of death (2013: 22.7%, 2014: 31.8%, 2015: 41.8%, 2016: 49.1%, and 2017: 57.9%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), driven by uptake of all agents except docetaxel. Adjusted odds of use were higher for patients seen at Regional Cancer Centers (OR: 1.8, 95% CI: 1.5\u20132.1) and who received prior prostate\u2010directed therapy (OR: 1.3, 95% CI: 1.0\u20131.5), but lower with advanced age (\u226585: OR: 0.54, 95% CI:0.39\u20130.75), increased chronic conditions (\u22656: OR: 0.62, 95% CI: 0.43\u20130.92), and long\u2010term care residency (OR: 0.38, 95% CI: 0.17\u20130.89). Income, stage at presentation, and distance to the cancer center were not associated with LPT uptake.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this cohort of prostate cancer\u2010decedents, real\u2010world uptake of novel prostate cancer therapies occurred at substantially higher rates for patients receiving care at Regional Cancer Centers, reinforcing the potential benefits for treatment access for patients referred to specialist centers.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.5401","type":"journal-article","created":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T06:54:23Z","timestamp":1668754463000},"page":"5569-5579","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A <scp>population\u2010based<\/scp> study of factors associated with systemic treatment in advanced prostate cancer decedents"],"prefix":"10.1002","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7431-3574","authenticated-orcid":false,"given":"Jennifer","family":"Leigh","sequence":"first","affiliation":[{"name":"Department of Medicine University of Ottawa  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danial","family":"Qureshi","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute  Ottawa Ontario Canada"},{"name":"Nuffield Department of Population Health University of Oxford  England UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Sucha","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute  Ottawa Ontario Canada"},{"name":"ICES University of Ottawa, Ottawa Hospital Research Institute  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshanak","family":"Mahdavi","sequence":"additional","affiliation":[{"name":"ICES University of Ottawa, Ottawa Hospital Research Institute  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igal","family":"Kushnir","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine Tel Aviv University  Tel Aviv Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke T.","family":"Lavall\u00e9e","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute  Ottawa Ontario Canada"},{"name":"Division of Urology, Department of Surgery The Ottawa Hospital and University of Ottawa  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Bosse","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Ottawa  Ottawa Ontario Canada"},{"name":"Ottawa Hospital Research Institute  Ottawa Ontario Canada"},{"name":"Division of Medical Oncology, Department of Medicine The Ottawa Hospital  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Webber","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute  Ottawa Ontario Canada"},{"name":"Bruy\u00e8re Research Institute  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Tanuseputro","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Ottawa  Ottawa Ontario Canada"},{"name":"Ottawa Hospital Research Institute  Ottawa Ontario Canada"},{"name":"ICES University of Ottawa, Ottawa Hospital Research Institute  Ottawa Ontario Canada"},{"name":"Bruy\u00e8re Research Institute  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ong","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Ottawa  Ottawa Ontario Canada"},{"name":"Ottawa Hospital Research Institute  Ottawa Ontario Canada"},{"name":"Division of Medical Oncology, Department of Medicine The Ottawa Hospital  Ottawa Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,11,17]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Ontario Cancer Statistics 2018 Report.\u201d2018.Cancer Care Ontario. January 8 2018.https:\/\/www.cancercareontario.ca\/en\/statistical\u2010reports\/ontario\u2010cancer\u2010statistics\u20102018\u2010report."},{"issue":"3","key":"e_1_2_11_3_1","first-page":"S92","article-title":"The burden of prostate cancer in Canada","volume":"3","author":"Fradet Y","year":"2009","journal-title":"Can Urol Assoc J"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2011.02799.x"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014618"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61389-X"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"issue":"3","key":"e_1_2_11_9_1","first-page":"213","article-title":"Alpha emitter Radium\u2010223 and survival in metastatic prostate cancer. New Eng","volume":"369","author":"Parker C","year":"2013","journal-title":"J Med"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.07.032"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051517-011947"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.21.00206"},{"issue":"2","key":"e_1_2_11_13_1","first-page":"29","article-title":"Neoadjuvant chemotherapy for muscle\u2010invasive bladder cancer: underused across the 49th parallel","volume":"13","author":"Raphael MJ","year":"2019","journal-title":"Can Urol Assoc J"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacr.2019.02.044"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-7-167"},{"issue":"12","key":"e_1_2_11_16_1","first-page":"1642","article-title":"Impact of geography on care delivery and survival for noncurable pancreatic adenocarcinoma: A population based analysis","volume":"18","author":"Yee EK","year":"2020","journal-title":"JNCCN"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2010.06.006"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605257"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.190211"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475420960426"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-8-200710160-00010"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-015-1733-2"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-016-1415-5"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.11.018"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-016-1281-y"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017264"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002249"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjd.2016.06.006"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2017.1150"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-14-469"},{"issue":"2","key":"e_1_2_11_31_1","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004302","article-title":"Adoption of sacubitril\/valsartan for the management of patients with heart failure","volume":"11","author":"Sangaralingham LR","year":"2019","journal-title":"Circ Heart Fail"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.03.540"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-12-56"},{"issue":"1","key":"e_1_2_11_34_1","first-page":"78","article-title":"Influences on the prescribing of new drugs","volume":"37","author":"Tobin L","year":"2008","journal-title":"Aust Fam Physician"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3657"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32486-3"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704174"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903307"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29576"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70288-8"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-019-00677-6"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5401","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.5401","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.5401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T16:17:34Z","timestamp":1692634654000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.5401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,17]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1002\/cam4.5401"],"URL":"https:\/\/doi.org\/10.1002\/cam4.5401","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,17]]},"assertion":[{"value":"2022-08-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}